New data presented by Mundipharma highlights a portfolio with cost efficient therapies
2 November 2013 | By Portland Communications
"Mundipharma recognises the current economic environment and resulting budget constraints for healthcare systems..."
List view / Grid view
News
Simeprevir administered once daily as part of combination therapy demonstrates sustained virologic response in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C adult patients
2 November 2013 | By Janssen R&D Ireland
“The breadth of simeprevir data presented at AASLD reinforce its potential as a treatment option..."
Merck announces presentation of interim data from study of investigational combination of HCV therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases annual meeting
2 November 2013 | By Merck
Sustained virologic response at post-treatment follow-up week 12 (SVR 12) seen in 100 percent of patients to date in two of the three combination arms studied...
BMS submits first all-oral, interferon-free and ribavirin-free treatment regimen for regulatory review in Japan for patients with chronic hepatitis C infection
2 November 2013 | By Bristol-Myers Squibb Company
"We are pleased to be one step closer to bringing a potential new treatment option to the many people living with HCV..."
Incivo®(Telaprevir) data to be presented at AASLD and ISPOR on the anit-viral response, safety, tolerability and cost-effectiveness of an Incivo based regimen in the treatment of genotype-1 chronic hepatitis C
1 November 2013 | By Janssen
Janssen continues to undertake clinical studies with telaprevir to identify opportunities to serve specialized and hard-to-treat patients...
Novo Nordisk receives FDA approval for FlexTouch® in the US
1 November 2013 | By Novo Nordisk
FlexTouch® is the latest innovation in prefilled insulin delivery systems from Novo Nordisk...
Novo Nordisk increased operating profit by 10% in the first nine months of 2013
31 October 2013 | By Novo Nordisk
Sales growth of 8% driven by Victoza®, Levemir® og NovoRapid®...
Marc Dunoyer appointed Chief Financial Officer of AstraZeneca
"Following a thorough and extensive search it became clear that Marc possessed the rare blend of financial, business and science experience..."
New Marketing Authorisation Application submitted to EMA for Ibrutinib for the treatment of two forms of blood cancer
30 October 2013 | By Johnson & Johnson
“The EMA Marketing Authorisation Application is an important milestone in the development of ibrutinib...”
Teva announces departure of President and CEO
30 October 2013 | By Teva Pharmaceutical Industries Ltd
Dr. Jeremy Levin will step down as President and Chief Executive Officer...
Abbott’s MitraClip® treatment demonstrates positive results for patients with degenerative mitral regurgitation at prohibitive risk for surgery
30 October 2013 | By Abbott
The MitraClip device provides physicians with a breakthrough treatment option for patients suffering from MR...
AstraZeneca advances MedImmune’s benralizumab to Phase III in severe asthma
30 October 2013 | By AstraZeneca
The goal of CALIMA is to determine whether benralizumab reduces the number of exacerbations in patients with severe asthma that remains uncontrolled...
Tecan’s AC Extraction Plate™ provides a unique sample preparation tool for LC-MS
29 October 2013 | By kdm communications
Tecan’s newly launched AC Extraction Plate is a revolutionary, automation-friendly solution designed to streamline sample preparation...
New partnership between GSK and the Bill & Melinda Gates Foundation to accelerate research into vaccines for global health needs
29 October 2013 | By GlaxoSmithKline
GSK and BMGF will invest a combined $1.8 million in early stage research into vaccine thermostability...
Merck announces presentation of interim data from phase 1B study of MK-3475, investigational anti-PD-1 immunotherapy
29 October 2013 | By Merck
“We are encouraged by these initial responses in NSCLC patients..."
